ESTRADERM
LOE ApproachingNDATRANSDERMALSYSTEM
Approved
Sep 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ESTRADERM is a transdermal estradiol delivery system approved in 1986 for hormone replacement therapy. The product delivers estrogen through the skin via a patch formulation, providing steady-state hormone levels. It treats symptoms associated with menopause and estrogen deficiency in women.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team downsizing and transition focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ESTRADERM represents a legacy brand in decline, offering limited career growth opportunity but valuable experience in lifecycle management and defending mature franchises. Roles will focus on maximizing remaining market share and preparing for generic competition.
Brand ManagerField Sales Representative
Worked on ESTRADERM at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.